Taysha Gene Therapies (NASDAQ:TSHA) filed a prospectus for a mixed shelf offering of up to $300 million. The preliminary prospectus is not an offer to sell. Filing Taysha Gene Therapies ...

The Japanese firm has agreed to make a $50 million investment in Dallas-based Taysha in exchange for a 15% stake in the company, plus exclusive options to license two clinical-stage, single-gene ...

Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Avi Kapoor Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" Neurogene (NASDAQ:NGNE ...

Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central ...

Taysha Gene Therapies (TSHA) announced that, on March 3, 2025, the Compensation Committee of Taysha’s Board of Directors granted three new employees, in the aggregate, options to purchase ...

Taysha Gene Therapies (TSHA) is scheduled to report earnings on May 13, 2025. The last reported earnings were for reported on February 26, 2025 for Q4. The Actual Revenue was $2M, which beat the ...